Biocept Inc (NASDAQ:BIOC) saw strong trading volume on Monday . 16,375 shares were traded during trading, a decline of 97% from the previous session’s volume of 474,952 shares.The stock last traded at $6.79 and had previously closed at $6.40.

Several equities analysts recently weighed in on the company. ValuEngine upgraded Biocept from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Westpark Capital reiterated an “outperform” rating and set a $1.00 target price on shares of Biocept in a research report on Wednesday, April 4th. Finally, Zacks Investment Research downgraded Biocept from a “buy” rating to a “hold” rating in a research report on Friday, May 11th.

The stock has a market capitalization of $16.33 million, a price-to-earnings ratio of -0.27 and a beta of 1.89. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.41 and a quick ratio of 2.31.

Biocept (NASDAQ:BIOC) last released its quarterly earnings data on Tuesday, May 15th. The medical research company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The firm had revenue of $0.81 million during the quarter, compared to analysts’ expectations of $1.21 million. Biocept had a negative return on equity of 445.14% and a negative net margin of 561.47%. analysts expect that Biocept Inc will post -9.01 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Biocept stock. Sabby Management LLC acquired a new position in Biocept Inc (NASDAQ:BIOC) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 962,265 shares of the medical research company’s stock, valued at approximately $668,000. Sabby Management LLC owned 1.51% of Biocept at the end of the most recent reporting period. Institutional investors and hedge funds own 7.56% of the company’s stock.

About Biocept

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Featured Article: Should you buy a closed-end mutual fund?

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.